Dysregulation of genes involved in organizing and maintaining nuclear structures, such as SYNE1, SYNE2, TREM43, EMD and LMNA is frequently associated with diverse diseases termed laminopathies, which often affect the muscle tissue. The PRR14 protein was recently reported to tether heterochromatin to nuclear lamina but its function remains largely unknown. Here, we present several lines of evidence demonstrating a critical role of PRR14 in regulation of myoblast differentiation. We found that Prr14 expression was upregulated during skeletal myogenesis. Knockdown of Prr14 impeded, whereas overexpression of PRR14 enhanced C2C12 differentiation. The pro-myogenesis activity of PRR14 seemed to correlate with its ability to support cell survival and to maintain the stability and structure of lamin A/C. In addition, PRR14 stimulated the activity of MyoD via binding to heterochromatin protein 1 alpha (HP1α). The results altogether support a model in which PRR14 promotes skeletal myogenesis via supporting nuclear lamina structure and enhancing the activity of MyoD. Cell Death and Disease (2015) 6, e1734; doi:10.1038/cddis.2015.103; published online 23 April 2015
The nuclear lamina is a scaffold-like network of protein filaments surrounding the nuclear periphery. [1] [2] [3] [4] [5] As an essential component of metazoan cells, it is involved in most nuclear activities, including DNA replication, RNA transcription, nuclear and chromatin organization, cell cycle regulation, cell development and differentiation, nuclear migration, and apoptosis. 6, 7 The nuclear lamina is composed of lamins, which are also present in the nuclear interior, and lamin-associated proteins. Specific mutations in nuclear lamina genes cause laminopathies, a group of rare genetic disorders presenting a large variety of clinical symptoms in different tissues. These diseases include Emery-Dreifuss muscular dystrophy, 4, 8 Atypical Werner syndrome, 9 dilated cardiomyopathy, 10 Buschke-Ollendorff syndrome, 11 Limb-girdle muscular dystrophy, 12 Hutchinson-Gilford progeria syndrome, 13 Barraquer-Simons syndrome, 14 Charcot-Marie-Tooth disease, 15 Pelger-Huet anomaly, 16 Pelizaeus-Merzbacher disease, 17 Tight skin contracture syndrome 18 and so on. Among all the different clinical presentations, muscle seems to be the most common target of laminopathies.
The lamin family of proteins consists of the matrix of nuclear lamina. There are three types, A, B and C, of lamins in humans, encoded by three genes: LMNA for A-type lamins (lamin A/C are encoded by the LMNA gene through alternate splicing), LMNB1 for lamin B1 and LMNB2 for lamin B2. In contrast to B-type lamins, which are ubiquitously present in all cell types, A-type lamin expression is largely restricted to differentiated tissues, particularly skeletal muscle. Among all the nuclear lamina components, LMNA is the first and most studied gene associated with laminopathies. Various mutations in LMNA have been reported to result in muscular dystrophies. 4, 12, [19] [20] [21] The mutations are located throughout the gene and they impair myogenesis either by resulting in mechanical weakness of the nuclear lamina and of the cells, especially in striated muscle cells, 22 or by regulation of gene expression through direct interactions with different transcription factors and chromatin-modifying complexes. 23 One of the critical functions of the nuclear lamina is to organize heterochromatin, 24 which, as part of nuclear chromatin architecture, has an important role in nuclear organization. Along with the nucleus, heterochromatin undergoes a global reorganization during myogenesis. Heterochromatin protein 1 isoform, a constitutive component of heterochromatin, is also implicated in myogenesis. 25, 26 Proline rich 14 (PRR14), a not well-studied protein, was recently reported to function as a structural protein that tethers heterochromatin to nuclear lamina through functional associations with HP1α and the nuclear lamin A/C. 5 Here, we provide evidence that uncovers a novel function of PRR14 in regulation of myoblasts differentiation and interestingly, PRR14 directly binds to HP1α and this binding has an important role during myogenesis.
Results
RNAi-mediated depletion of Prr14 inhibits myoblast differentiation. PRR14 was reported to be functionally related with lamin A/C, 5 which is implicated in myogenesis. 4, 12, [19] [20] [21] We asked whether PRR14 might contribute to the regulation of myogenesis. To address this question, we measured the expression of Prr14 during the course of C2C12 myoblast differentiation. Using quantitative RT-PCR analysis, we observed that the Prr14 transcript level was indeed increased at day 1 upon differentiation induction and sustained thereafter (Figure 1a ). The upregulation of Prr14 was confirmed at the protein level, which co-related with the induction of myosin heavy chain (MHC), a surrogate marker of the skeletal muscle differentiation (Figures 1b and c) . It has been demonstrated that the differentiation of skeletal muscle continues after birth until the adult stage. 27 We collected mouse gastrocnemius muscle from newborn and 10-week-old mice (C57BL/6 J, 000664, JAX) to determine the expression of PRR14. The result showed that the PRR14 protein level in the skeletal muscle is significantly higher in 10-week-old mice than in newborn mice (Figures 1d and e) . Collectively, both in vitro and in vivo data revealed an increased PRR14 expression during skeletal muscle differentiation.
To investigate the functional significance of PRR14 induction during myoblast differentiation, we employed the siRNA-mediated method to deplete its expression. A mix of three different siRNAs (SASI_Mm01_00110458, SASI_Mm01_00110459 and SASI_Mm01_00110460, Sigma, St. Louis, MO, USA) targeting three different sites of Prr14 was used to generate Prr14-deficient C2C12 cells. qRT-PCR analysis showed that Prr14-specific siRNAs efficiently reduced its mRNA level to about 40%, relative to the nonspecific control (Figure 2a ; more complete depletion was associated significant cell death is not shown). The cells were assessed for their myogenic potential by culturing in differentiation media (DM) for 5 days. Examination of phase-contrast images revealed that C2C12 cells expressing control siRNA developed into myotubes as expected; however, myotube formation was considerably impaired in cells expressing Prr14 siRNA (Figure 2b ). As C2C12 differentiation is associated with the formation of multinuclear myotube, we measured the cells with multinuclei to quantify the effect of PRR14. By defining the fusion index as the percentage of cells with three or more nuclei, we quantified cells with multinuclei via FACS analysis. The result revealed a significant decrease in the number of multinuclear cells in Prr14 RNAi-expressing cells relative to the control RNAi cells (24 versus 34%, Po0.05, Figure 2c ). Immunofluorescence analysis of MHC was performed to verify the morphological data. Consistent with the formation of multinuclei myotubes, MHC protein was highly expressed upon induction of differentiation in control RNAi-expressing cells. In contrast, the expression of MHC was markedly diminished in Prr14 siRNA-expressing cells (Figure 2d ). The results together indicate that reduced PRR14 expression impeded C2C12-cell differentiation, suggesting a critical role of PRR14 in myoblasts differentiation.
PRR14 overexpression promoted the differentiation of C2C12 myoblasts. The protein sequence alignment data (available from: http://www.uniprot.org) showed that PRR14 protein sequences are highly conserved during the evolution and the protein sequences between human and mouse share over 72% similarity and 77% positive (Supplementary Figure  S1A) . When expressed in mouse C2C12 myoblasts, the Figure S1B) . Of note is the colocalization of PRR14 with the highly dense DAPI-rich structure, suggesting an association of PRR14 in the heterochromatin. This expression pattern is consistent with previously reported data in human cells. 5 With the finding that PRR14 underexpression was associated with impediment of C2C12 myoblasts differentiation, we hypothesized that PRR14 overexpression would enhance differentiation. We tested this hypothesis by introducing highly conserved human PRR14 into C2C12 cells. The C2C12-cell line stably expressing PRR14 was established through a retrovirus-mediated gene transfer. The expression of PRR14 was confirmed by immunoblot ( Figure 3a ). Upon induction of differentiation for 4 days, morphological examination detected more myotubes in PRR14-overexpressing C2C12 myoblasts than the empty vector-expressing control cells (Figure 3b ). FACS analysis of the fusion index showed that PRR14-overexpressing C2C12 cells had 93% cells with multinuclei, whereas the control cells had only 76% cells with multinuclei (Po0.05, Figure 3c ). The enhanced differentiation by PRR14 was further confirmed via MHC immunostaining ( Figure 3d ). Together, our data indicate that PRR14 overexpression promotes myogenesis.
To better characterize the role of PRR14 in myogenesis, we performed a time-course experiment to monitor the kinetics of myoblasts differentiation. After culturing in growth medium for 12 h, C2C12 cells were transferred to DM and collected at the indicated time points. Immunostaining of MHC detected its expression at 48 h after incubation in DM. As expected, MHC expression increased as a function of time. Notably the induction of MHC in PRR14-overexpressing cells was markedly increased when compared with the vector-expressing control cells (Figure 4a ), consistent with a role for PRR14 in promoting myogenesis. This effect of PRR14 was validated via immunoblot analysis of MyoG, another surrogate marker of myotubes. In agreement with MHC expression, the MyoG protein abundances were higher in PRR14-expressing cells than the control cells ( Figure 4b ). As both MHC 28, 29 and MyoG 30 are direct targets of MyoD during myogenesis in skeletal muscle, which is a major transcription factor regulating the expression of many myogenesis-associated genes, we measured the expression PRR14 protects cells from apoptosis during myogenesis. While observing myoblast differentiation, we noticed more survival cells in PRR14-expressing cells than the vector-control expressing cells (Figure 3b ). To quantify the difference, we used FACS analysis to measure the sub-G1 population. There were 22% apoptotic cells in the control cells and only 6% in PRR14-overexpressing cells during differentiation (Po0.05, Figure 5a ). To confirm the data, we carried out TUNEL assay (In Situ Cell Death Detection Kit, Fluorescein, Roche, Mannheim, Germany). Consistently, there were much less TUNEL-positive cells in PRR14-expressing C2C12 cells (Figure 5b ). The result implicates that PRR14 facilitated myoblast differentiation by inhibition of apoptotic cell death.
Knockdown of Prr14 was associated with downregulation of lamin A/C and HP1α. As PRR14 is reported to function as a bridge between lamin A/C and HP1α, 5 we asked whether Prr14 depletion might have any effect on them, which have been shown to be important during myogenesis. To this end, we examined lamin A/C in Prr14-depleted cells. To circumvent the lack of an anti-PRR14 antibody suitable for immunostaining, we co-expressed GFP with siRNA to facilitate the identification of Prr14-deficient cells. Interestingly, siRNAmediated Prr14 knockdown in C2C12 cells led to decrease in lamin A/C protein abundance (Figure 6a ). Approximately 15% of the cells showed weaker immunostaining (Figure 6c ). In addition, Prr14-deficient cells also displayed an abnormal nuclear morphology (Figure 6a, arrow) . The effect of PRR14 on lamin A/C appeared to be specific as lamin B1, another type of lamin, was not significantly affected under the same condition (Figures 6b and e) . Immunoblot confirmed the decrease in lamin A/C, and interestingly the level of HP1α was also reduced (Figures 6e and f) . qRT-PCR analysis did not detect a significant change in the transcripts of both lmna and Hp1α (Figure 6d) , suggesting that the decrease of lamin A/C Mutation disrupting the interaction between PRR14 and HP1α impairs C2C12 myogenesis. HP1α was suggested to mediate the association between PRR14 and heterochromatin. 5 It is, however, unclear regarding the nature of this interaction. We tested whether PRR14 might directly bind to HP1α by performing immunoprecipitation. Lysates from cells expressing Flag-tagged full-length, N-terminal or C-terminal constructs of PRR14 (Figure 7a ) were subjected to Flag-IP. Flag-MDM4, an unrelated protein, was included as a control. The result revealed a clear binding of full-length and N-terminal PRR14, but not C-terminal PRR14 and MDM4, to HP1α (Figure 7c) . Reciprocally, Flag-tagged HP1α was able to pull down co-expressed GFP-PRR14, but not GFP alone (Figure 7e ). To further determine whether the putative HP1-binding domain within the N-terminus is responsible for the binding, we introduced mutations within this region (Figure 7b ), which is conserved between human and mouse (Supplementary Figure S1A) . The result from co-IP experiment indicated a diminished binding of the mutant to HP1α (Figure 7d) . Together, the data indicate that PRR14 binds to HP1α through its N-terminal HP1-binding motif.
HP1α was reported to interact with MyoD and to regulate its transcriptional activity. 26 Given that PRR14 binds to HP1α and MyoD induction during myoblast differentiation was greater in PRR14-expressing than control cells (Figure 4b ), we asked whether PRR14 might affect MyoD transcriptional activity through its interaction with HP1α. We addressed this question Figure 4 The effect of PRR14 on C2C12 differentiation kinetics. PRR14-or control vector-expressing cell lines were plated and cultured in GM for 24 h, then cell medium was replaced by DM. Cells were collected for either immunostaining (a) or immunoblot (b) at the indicated time points PRR14 in skeletal myogenesis M Yang and Z-M Yuan by employing luciferase assays (E1960, Promega, Madison, WI, USA) using a luciferase reporter driven by the muscle creatine kinase (MCK) promoter, a direct target of MyoD during myogenesis. 31 Although having little activity by itself, HP1α augmented the activity of MyoD, consistent with a positive regulation of MyoD transcriptional activity by HP1α. This result is consistent with the data shown in Figure 4b that PRR14 stimulated MyoD transcriptional activity. Interestingly, PRR14 showed little activity by itself but enhanced the effect of HP1α on MyoD activity. In line with its HP1α-binding mediated activity, the PRR14 mutant defective in HP1α binding failed to induce a similar effect (Figure 7f ). In addition, the mutant PRR14 seemed to be able to suppress wild-type PRR14's ability to enhance MyoD activity (Figure 7g ), which suggests a dominant-negative effect of this RR14 mutant.
Considering that MyoD is a master transcription factor of myogenesis, we examined whether PRR14/HP1α-dependent regulation of MyoD could impact on differentiation. For this, we created C2C12 cells stably expressing the HP1α-binding mutant of PRR14 and assessed its differentiation potential (Figure 8a) . Remarkably, expression of this PRR14 mutant almost completely prevented C2C12 myoblasts from differentiation, as demonstrated by the lack of appearance of multinucleated myotubes (Figures 8b and c) , significantly diminished expression of MHC (Figure 8d) , and a marked increase of apoptosis (Figures 8e-g ). The results together implicate that binding of PRR14 to HP1α is critical for its role in MyoD-mediated C2C12 myoblast differentiation.
Discussion
Many different mutations in LMNA, as well as other nuclear lamina-coding genes have been linked to several different inherited diseases with muscular dystrophy. 4, 12, [19] [20] [21] It remains incompletely clear how mutations in these proteins, expressed in nearly all differentiated somatic cells, cause such a tissue-specific phenotype. There are currently two prevailing but nonexclusive models. [32] [33] [34] [35] [36] [37] [38] [39] The 'mechanical stress' model is based on the observation that cells with decreased or mutated nuclear lamina protein often exhibit severe abnormalities in nuclear morphology. 32, 33, 40 Therefore, it is hypothesized that the nuclear lamina defines the shape and mechanical properties of the nucleus. Its structural alterations may lead to increased fragility and decreased mechanical stiffness, resulting in whole-cell mechanical vulnerability. 34, 35 During myogenesis, single-nuclear myoblasts align in parallel and fuse into multinucleated myotubes to complete the differentiation process. Such dramatic morphological alterations are associated with considerable mechanical stress. In addition to the contractile properties of muscle fibers, this is likely one of reasons why the muscle tissue is more susceptible to dysregulation of nuclear lamina-coding genes.
Consistent with its unique distribution in the lamina, siRNAmediated Prr14 depletion was associated with dysregulation of lamin A/C (Figure 6 ). Although lacking direct evidence for an interaction between PRR14 and lamin A/C, these two proteins seem to be functionally related. Poleshko et al. 5 reported that siRNA-mediated lamin A/C depletion was associated with releasing PRR14 from nuclear lamina in Hela cells. Our data is also consistent with an interaction between PRR14 and lamin A/C as evidenced by the observation that Prr14 depletion resulted in marked reduction of lamin A/C abundance in C2C12 cells. Although further studies are needed to elucidate the underlying mechanism, our data suggest that PRR14 enhances myogenesis via, at least, in part maintaining the protein stability of lamin A/C and thus structure of lamina. Considering the critical role for lamin A/C in supporting the nuclear lamina structure, reduced lamin A/C abundance would likely compromise nuclear organization. The mechanical stress model seems to be in line with PRR14-mediated regulation of myogenesis.
Nuclear lamina dynamically interacts with chromatin and contributes to chromatin hierarchical organization, 36, 37 which undergoes drastic changes during muscle-cell differentiation. 38 The second model or 'gene expression' model proposes that, in addition to its structural and mechanical function, nuclear organization has a role in differentiation through regulation of tissue-specific gene expression. We showed that PRR14 augmented the transcriptional activity of MyoD via directly binding to HP1α, a constitutive component of heterochromatin involved in regulation of gene expression and higher-order chromatin structure. 39 It was previously reported that siRNA-mediated depletion of Hp1α impairs myogenesis in C2C12 cells, 25, 26 and HP1α participates in not only reorganization of heterochromatin but selective regulation of tissue-specific genes during neuron cell differentiation. 41 The PRR14/HP1α interaction-induced MyoD stimulation uncovered by the present study offers novel insight into the gene expression model in regulation of myogenesis.
The PRR14 gene is located in 16p11.2. There were only eight reported cases with copy number variations (deletions) surrounding this locus. Six out of the eight cases have shown signs of developmental delay. Interestingly, hypotonia underlies delay in two out of four children with delayed mobility skills. 42 Further study is warranted to investigate the association of PRR14 with human laminopathies.
Materials and Methods
Cell culture, transfection and stable cell lines establishment. C2C12 and HEK293T were maintained using standard conditions. C2C12 cells were induced to differentiate into myotubes in differentiation medium (DMEM high glucose supplemented with 4 mM glutamine, 100 IU ml − 1 penicillin, 100 μg ml − 1 streptomycin, and 2% (v/v) horse serum). DNA transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). siRNA transfection was mediated by Lipofectamine RNAiMAX Transfection Reagent (Invitrogen).
Retroviral production and infection were done following the protocol from Clontech. Cells were allowed to recover for 24 h prior to selection with hygromycin for 1 week. Cells transduced with the empty vector were also established and used as control cell lines.
Plasmids. cDNA encoding full-length human PRR14 was purchased from DF/ HCC DNA Resource Core (Boston, MA, USA) and cloned into pQCXIH (Clontech) for retrovirus production and pEGFP-N1 (Clontech) by Gateway Cloning system (Invitrogen). For deletion mutation, the full-length plasmid was used as template for PCR with the following primers: NPRR14-F: CGGAATTCCCATGGACTTGCCCGGG GAC, NPRR14-R: CTAGTCTAGACGAGGGGGTGGCGGGGCTCG, CPRR14-F: CGGAATTCCCATGCCCTGTCTCCGGAAAGAGG, CPRR14-R: CTAGTCTAGAGGT CCAGTGGGGCTG. Site-directed mutation was introduced by Q5 Site-Directed Mutagenesis Kit (NEB, Ipswich, MA, USA) using primers: PRR14a-F: GTCCTGGCCGCGGCGCTAGAAGATG and PRR14a-R: CCGCCGAGAGGCCTT TTC.
All plasmids were sequenced to confirm the insertion. For dual-luciferase assay, plasmids MCK-luciferase (#16062, addgene, Cambridge, MA, USA), pRL-TK (Promega), myc-MyoD (#8399, addgene) and GFP-HP1α (#17652, addgene) were purchased.
RNA preparation, reverse transcription and qPCR. Total RNA was extracted using the standard TRIzol method (Life Technologies, Grand Island, NY, USA) and used for the first-strand cDNA synthesis by iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with SYBR Green JumpStart Taq ReadyMix (Sigma) using the StepOnePlus Real-Time PCR System (Bio-Rad). All reactions were run in duplicate. After vortexing, 10 μl aliquots of the mixture were pipetted into each well of a 96-well thin-wall PCR plate (Bio-Rad). PCRs consisted of a denaturing cycle at 94°C for 2 min, followed by 40 cycles of Cell cycle analysis. C2C12 cells were trypsinized, collected by centrifugation (500 g, 5 min), washed in 4°C PBS once and gently resuspended in 1 ml hypotonic fluorochrome solution (PI 50 μg ml − 1 in 0.1% sodium citrate, 10 mM NaCl, 0.3% NP-40 plus 25 mg ml − 1 RNase) in polypropylene tubes, followed by incubation in 37°C for 30 min. The tubes were placed at 4°C in darkness for flow cytometric analysis.
Immunohistochemistry, western blotting and immunoprecipitation. For western blot, cells were lysed in NP-40 buffer (150 mM NaCl, and #8232; 1% NP-40, 50 mM Tris-HCl, pH 8.0, 0.1% SDS) supplemented with phosphatase and protease inhibitors (1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 1 mM EDTA, 1 μg ml − 1 aprotinin, 1 μg ml − 1 leupeptin). Western analysis was performed using standard procedures and the protein of interest was normalized to β-actin protein level. For immunohistochemistry, cells were fixed in ice cold 1 : 1 Acetone/methanol fixative, and blocked with 1% BSA/1% Triton X-100/1 X PBS. The following antibodies were used: Flag (clone M5, Sigma), HP1α (#2616, Cell Signaling, Beverly, MA, USA), MHC (clone A4.1025, Millipore, Temecula, CA, USA), lamin A/C (#4777; Cell Signaling, Danvers, MA, USA), MyoD diluted at 1 : 100 (sc-760; Santa Cruz, Santa Cruz, CA, USA), PRR14 (ab174532, abcam, Cambridge, MA, USA), Histone H3 (tri methyl K9; ab8898, abcam), lamin B1 (sc-6216; Santa Cruz) and β-actin (clone ab8226; abcam). Immunoprecipitation was done in HEK293T cells. After 48 h transfection, cells were collected and lysed in RIPA buffer (25 mM TrisHCl, (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) and incubated with flag beads (Anti-FLAG M2 magnetic Beads, Sigma). Immunoprecipitation was performed following the protocol.
Statistical analysis. The data are presented as mean ± S.D. Two-tailed student's t-test was used to determine the significance of the difference between the two groups. If not indicated otherwise, the criterion for significance was set at P ⩽ 0.05 (Prism 6, GraphPad Software, San Diego, CA, USA).
